 <h1>Gemtuzumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to gemtuzumab: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with gemtuzumab ozogamicin</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, gemtuzumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking gemtuzumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>bone pain</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>coughing up blood</li>
<li>decreased urine output</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness, lightheadedness, or fainting</li>
<li>dry mouth</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>headache</li>
<li>hoarseness</li>
<li>increased hunger</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>lower back or side pain</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>nosebleeds</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful or difficult urination</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>prolonged bleeding from cuts</li>
<li>rapid, shallow breathing</li>
<li>rash</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>seizures</li>
<li>sore throat</li>
<li>stomach pain and bloating</li>
<li>sweating</li>
<li>swelling of the face, ankles, or hands</li>
<li>tightness in the chest</li>
<li>unexplained weight loss</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blue lips and fingernails</li>
<li>coughing that sometimes produces a pink frothy sputum</li>
<li>difficult, fast, noisy breathing</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>increased sweating</li>
<li>pale skin</li>
<li>ulcers, sores, or white spots in the mouth</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Stomach cramps</li>
<li>watery or bloody diarrhea</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of gemtuzumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cracked lips</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to gemtuzumab: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Bleeding (25%), thrombocytopenia (24%), febrile neutropenia (18%)</p>
<p><b>Common</b> (1% to 10%): Hemorrhage </p>
<p><b>Frequency not reported</b>: Myelosuppression, anemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (79%), fatigue (46%)</p>
<p><b>Common</b> (1% to 10%): Pain</p>
<p><b>Frequency not reported</b>: Chills<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (21%), vomiting (21%), constipation (21%), mucositis (21%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea</p>
<p><b>Postmarketing reports</b>: Neutropenic colitis (sometimes fatal)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, lung edema</p>
<p><b>Frequency not reported</b>: Hypoxia, respiratory failure, dyspnea</p>
<p><b>Postmarketing reports</b>: Fungal lung infections (including Pulmonary mycosis and Pneumocystis jirovecii pneumonia) (sometimes fatal), interstitial pneumonia (sometimes fatal)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (40%), increased ALT (16%)</p>
<p><b>Common</b> (1% to 10%): Veno-occlusive liver disease (VOD) (sometimes fatal), hyperbilirubinemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Postmarketing reports</b>: Hemorrhagic cystitis (sometimes fatal)</p>
<p>Genitourinary side effects have included vaginal hemorrhage (12%) and hematuria (10%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (44%), sepsis (32%)</p>
<p><b>Postmarketing reports</b>: Bacterial infections (including Stenotrophomonas infection), potential for immunogenicity<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal failure secondary to tumor lysis syndrome<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p>
<p><b>Frequency not reported</b>: QT interval prolongation, hypotension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (16%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (64%), hypokalemia (57%), hyponatremia (44%), alkaline phosphatase increased (13%), aspartate aminotransferase increased (14%), alanine aminotransferase increased (10%)</p>
<p><b>Common</b> (1% to 10%): Blood bilirubin increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity (including anaphylaxis)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Mylotarg (gemtuzumab)" Wyeth-Ayerst Laboratories, Philadelphia, PA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about gemtuzumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: CD33 monoclonal antibodies</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gemtuzumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Mylotarg</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Myeloid Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to gemtuzumab: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Bleeding (25%), thrombocytopenia (24%), febrile neutropenia (18%)</p><p><b>Common</b> (1% to 10%): Hemorrhage </p><p><b>Frequency not reported</b>: Myelosuppression, anemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (79%), fatigue (46%)</p><p><b>Common</b> (1% to 10%): Pain</p><p><b>Frequency not reported</b>: Chills<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (21%), vomiting (21%), constipation (21%), mucositis (21%)</p><p><b>Common</b> (1% to 10%): Diarrhea</p><p><b>Postmarketing reports</b>: Neutropenic colitis (sometimes fatal)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia, lung edema</p><p><b>Frequency not reported</b>: Hypoxia, respiratory failure, dyspnea</p><p><b>Postmarketing reports</b>: Fungal lung infections (including Pulmonary mycosis and Pneumocystis jirovecii pneumonia) (sometimes fatal), interstitial pneumonia (sometimes fatal)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (40%), increased ALT (16%)</p><p><b>Common</b> (1% to 10%): Veno-occlusive liver disease (VOD) (sometimes fatal), hyperbilirubinemia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Postmarketing reports</b>: Hemorrhagic cystitis (sometimes fatal)</p><p>Genitourinary side effects have included vaginal hemorrhage (12%) and hematuria (10%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection (44%), sepsis (32%)</p><p><b>Postmarketing reports</b>: Bacterial infections (including Stenotrophomonas infection), potential for immunogenicity<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal failure secondary to tumor lysis syndrome<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Tachycardia</p><p><b>Frequency not reported</b>: QT interval prolongation, hypotension<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (16%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypophosphatemia (64%), hypokalemia (57%), hyponatremia (44%), alkaline phosphatase increased (13%), aspartate aminotransferase increased (14%), alanine aminotransferase increased (10%)</p><p><b>Common</b> (1% to 10%): Blood bilirubin increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity (including anaphylaxis)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Mylotarg (gemtuzumab)" Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><h2>More about gemtuzumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>2 Reviews</li>
<li>Drug class: CD33 monoclonal antibodies</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gemtuzumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Myeloid Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>